🎉 M&A multiples are live!
Check it out!

D&D Pharmatech Valuation Multiples

Discover revenue and EBITDA valuation multiples for D&D Pharmatech and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

D&D Pharmatech Overview

About D&D Pharmatech

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.


Founded

2014

HQ

South Korea
Employees

n/a

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$333M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

D&D Pharmatech Financials

D&D Pharmatech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, D&D Pharmatech achieved revenue of $7.8M and an EBITDA of -$16.5M.

D&D Pharmatech expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See D&D Pharmatech valuation multiples based on analyst estimates

D&D Pharmatech P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $12.7M $7.8M XXX XXX XXX
Gross Profit $0.4M $12.7M XXX XXX XXX
Gross Margin 3% 163% XXX XXX XXX
EBITDA $7.1M -$16.5M XXX XXX XXX
EBITDA Margin 55% -212% XXX XXX XXX
Net Profit -$92.7M $2.7M XXX XXX XXX
Net Margin -729% 34% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

D&D Pharmatech Stock Performance

As of April 15, 2025, D&D Pharmatech's stock price is KRW 48350 (or $33).

D&D Pharmatech has current market cap of KRW 510B (or $347M), and EV of KRW 489B (or $333M).

See D&D Pharmatech trading valuation data

D&D Pharmatech Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$333M $347M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

D&D Pharmatech Valuation Multiples

As of April 15, 2025, D&D Pharmatech has market cap of $347M and EV of $333M.

D&D Pharmatech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate D&D Pharmatech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for D&D Pharmatech and 10K+ public comps

D&D Pharmatech Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $333M XXX XXX XXX
EV/Revenue 42.8x XXX XXX XXX
EV/EBITDA -20.2x XXX XXX XXX
P/E -17.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -22.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get D&D Pharmatech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

D&D Pharmatech Valuation Multiples

D&D Pharmatech's NTM/LTM revenue growth is n/a

D&D Pharmatech's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, D&D Pharmatech's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate D&D Pharmatech's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for D&D Pharmatech and other 10K+ public comps

D&D Pharmatech Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -39% XXX XXX XXX XXX
EBITDA Margin -212% XXX XXX XXX XXX
EBITDA Growth -334% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 12% XXX XXX XXX XXX
G&A Expenses to Revenue 11% XXX XXX XXX XXX
R&D Expenses to Revenue 204% XXX XXX XXX XXX
Opex to Revenue 319% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

D&D Pharmatech Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Drug Delivery Systems comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

D&D Pharmatech M&A and Investment Activity

D&D Pharmatech acquired  XXX companies to date.

Last acquisition by D&D Pharmatech was  XXXXXXXX, XXXXX XXXXX XXXXXX . D&D Pharmatech acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by D&D Pharmatech

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About D&D Pharmatech

When was D&D Pharmatech founded? D&D Pharmatech was founded in 2014.
Where is D&D Pharmatech headquartered? D&D Pharmatech is headquartered in South Korea.
Is D&D Pharmatech publicy listed? Yes, D&D Pharmatech is a public company listed on KRX.
What is the stock symbol of D&D Pharmatech? D&D Pharmatech trades under 347850 ticker.
When did D&D Pharmatech go public? D&D Pharmatech went public in 2024.
Who are competitors of D&D Pharmatech? Similar companies to D&D Pharmatech include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of D&D Pharmatech? D&D Pharmatech's current market cap is $347M
What is the current revenue growth of D&D Pharmatech? D&D Pharmatech revenue growth between 2023 and 2024 was -39%.
Is D&D Pharmatech profitable? Yes, D&D Pharmatech is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.